Research Topic: Psychedelic-assisted therapy

Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies

mycolabadmin

This research review examined whether people with schizophrenia can safely participate in psychedelic-assisted therapy treatments. Researchers analyzed 131 studies and found that psychedelics rarely cause new psychosis in the general population (0.002%), though the risk is slightly higher in people with existing schizophrenia (3.8%). While the immediate risk appears manageable, about 13% of people who develop psychosis from psychedelics go on to develop schizophrenia, suggesting caution is still needed.

Read More »

Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study

mycolabadmin

This study examined how childhood trauma can resurface during psychedelic experiences and what happens afterward. Researchers surveyed over 600 people who had difficult experiences after using psychedelics, and interviewed 18 of them in detail. They found that trauma surfaced in different ways—some people vividly relived events, others felt intense bodily sensations, and some experienced confusion. About half of participants found healing from the experience, while others struggled with ongoing trauma symptoms or mixed outcomes. The research emphasizes the importance of proper preparation, supportive settings, and follow-up integration work to help people process these experiences safely.

Read More »

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting

mycolabadmin

A research study examined how psilocybin experiences affect long-term mental health and well-being in healthy volunteers. Participants received two doses of psilocybin in controlled medical settings while undergoing brain imaging. The study found that psilocybin consistently produced positive, lasting improvements in mood, well-being, and spiritual outlook, regardless of whether people had used psychedelics before, their sex, or the specific imaging setting used.

Read More »

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

mycolabadmin

This Australian study surveyed over 500 people about their views on psychedelics like psilocybin and MDMA for treating mental health conditions. Most people supported medical legalization of these substances, though many had safety concerns. Those with mental illness, those with prior psychedelic experience, and those with better knowledge of psychedelics were most supportive of their therapeutic use.

Read More »

Psilocybin: Systematic review of its use in the treatment of depression

mycolabadmin

Researchers reviewed scientific studies on psilocybin, a psychedelic compound found in certain mushrooms, as a treatment for depression. The studies showed that psilocybin significantly reduced depressive symptoms faster than standard treatments, with minimal side effects. This suggests psilocybin could be a promising new option for people with depression who haven’t benefited from traditional medications.

Read More »

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds

mycolabadmin

Scientists extracted and analyzed psilocybin and psilocin from Psilocybe cubensis mushrooms to develop a medication for treating mental health disorders like depression and anxiety. Using various analytical techniques, they confirmed the extract contained about 3.26% psilocybin and was safe, pure, and stable. The research shows that creating a psilocybin-based medicine from these mushrooms is feasible and could offer a new treatment option for people struggling with mental health issues.

Read More »
Scroll to Top